Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...

Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality a...

Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounja...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gain...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...

A new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating habits. The stud...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resor...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...

Novo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure suff...

SVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...